Neuroprotective agents in schizophrenia and affective disorders.
With the exception of dementia, the use of neuroprotective agents in psychiatric disorders is not yet well established. However, recent data from brain imaging studies and clinical trials support the view that neurodegenerative mechanisms may play a role in the pathophysiology of schizophrenia and affective disorders. Further evidence for the use of neuroprotective agents can be drawn from the findings that second-generation antipsychotics, mood stabilizers and antidepressants have been shown to have neuroprotective effects in vitro and in vivo. Neuroprotective agents as add-on therapies (e.g., modafinil, erythropoietin, glycine, D-serine, memantine and celecoxib) are currently being evaluated in schizophrenia and related disorders. This paper reviews the current options for neuroprotective treatment approaches focusing on schizophrenia and affective disorders.
Krebs
Michael
M
Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Schumannstr. 20/21, D-10117 Berlin, Germany. Michael.Krebs@charite.de
Leopold
Karolina
K
Hinzpeter
Axel
A
Schaefer
Martin
M
D000818:Animals; D006801:Humans; D019964:Mood Disorders / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000517:prevention & control
D018696:Neuroprotective Agents